hVIVO's Orderbook Surges to £65 Million Amid Robust H1 2026 Commercial Growth and Strong Future Revenue Visibility

Orderbook Growth Highlights Strengthened Commercial Traction and Enhanced Revenue Visibility

hVIVO’s orderbook expanded substantially from £30 million at the start of 2026 to £65 million, marking a significant milestone that improves forward revenue visibility through 2026, 2027, and into 2028. This more than twofold increase in contracted business provides greater certainty over future revenue streams and reflects one of the company’s strongest periods of new contract acquisitions. The growth is supported by vigorous business development efforts, with proposal volumes rising approximately 45% year-on-year, indicating sustained client engagement across hVIVO’s diversified service offerings and potential for further orderbook expansion throughout the remainder of 2026.

The company’s integrated single-platform approach is driving enhanced commercial results, with services increasingly contracted under the unified hVIVO brand rather than separate business units. This consolidation has fostered cross-selling opportunities and broadened the client base, reducing concentration risk and promoting balanced revenue generation. Clients are engaging more comprehensively with hVIVO’s full suite of capabilities, including consulting, clinical trials, human challenge trials, and laboratory services, rather than utilizing isolated services.

H1 2026 Revenue Decline Reflects Expected Contract Timing, Not Demand Weakness

Revenue of £16.3 million in H1 2026 declined from £24.2 million in H1 2025; however, this decrease aligns with the anticipated second-half weighting of 2026 activities and timing shifts in revenue recognition for certain client programs, rather than a drop in underlying demand. The company had previously guided that 2026 revenues would be weighted toward the latter half of the year, with numerous contracted projects commencing in upcoming months. This visibility, combined with the expanded orderbook, indicates the H1 revenue dip is a temporary timing effect rather than a sign of weakening momentum.

Some programs have experienced modest deferrals from H2 2026 into 2027, shifting expected revenues accordingly. Despite this, the board reaffirms its expectation of high single-digit revenue growth for the full year 2026, underscoring confidence in the strength of contracted business and sustained revenue expansion. The announcement clarifies that these deferrals are timing adjustments, not cancellations or reductions in contract value.

Adjusted EBITDA Forecast to Improve from H1 Negative to H2 Positive Driven by Revenue Growth

hVIVO anticipates a mid-single digit negative adjusted EBITDA in H1 2026, compared to £3.0 million in H1 2025, reflecting the impact of lower first-half revenues against a relatively fixed cost base. This swing illustrates the operational leverage inherent in hVIVO’s model, where fixed costs related to clinical trial facilities, laboratories, and personnel are spread over variable revenues concentrated in specific periods. Management expects this trend to reverse in H2 2026, with positive adjusted EBITDA projected as higher revenues materialize.

Notably, there are no exceptional items reported for 2026, compared to £1.4 million in 2025, indicating an absence of significant one-off costs or restructuring charges this year. This improved cost profile, coupled with anticipated increased second-half revenues from the expanded orderbook, supports management’s expectation of positive adjusted EBITDA in H2 2026. The extent of profitability improvement will depend on revenue timing and cost control, key factors investors will monitor.

Strong Cash Position and Working Capital Inflows Bolster Financial Flexibility

As of 30 June 2026, hVIVO held £13 million in cash, a slight decrease from £14.3 million at 31 December 2025. The reduction reflects positive working capital inflows from recent contract wins rather than operational cash burn or financial deterioration. The company maintains financial flexibility to invest in growth initiatives, with management confident in the firm’s financial strength. The modest cash decline amid significant orderbook growth suggests contract wins have generated working capital benefits such as advance payments or favorable terms, offsetting operational cash outflows.

While capital expenditure and working capital needs for H2 2026 were not disclosed, the emphasis on positive working capital inflows and liquidity indicates no immediate concerns regarding financial sustainability. Given the company’s substantial facilities, including the world’s largest human challenge trial quarantine site in London, and international operations in the UK and Germany, cash and working capital management remain critical for navigating uneven revenue recognition.

Diversified Service Platform Enhances Revenue Stability and Lowers Concentration Risk

hVIVO delivers integrated services across consulting, clinical trials, human challenge trials, and laboratory services, offering preclinical strategy, first-in-human studies, Phase II trials, and specialist laboratory support via a large participant database and wholly owned UK and German sites. With over 100 years of combined heritage, the company benefits from operational experience and strong client relationships across the clinical development spectrum. Operating under a single brand across all services enables cross-selling and encourages clients to engage comprehensively with hVIVO’s capabilities rather than fragmenting spending among multiple vendors.

This diversified model supports a balanced and resilient revenue profile compared to prior years when service lines operated more independently. The announcement highlights encouraging demand across infectious disease, respiratory, and cardiometabolic programs, alongside rising interest in early-phase CRO and laboratory services. This broad demand base reduces concentration risk and differentiates hVIVO from competitors with narrower offerings, strengthening pricing power and client retention.

Client and Capital Markets Engagement Validate Commercial Momentum

hVIVO recently hosted a Capital Markets Day featuring presentations from clients, investors, and industry experts, with recordings available on its website. This event validated the strength of hVIVO’s integrated drug development model, with client participation indicating satisfaction and deepening partnerships. Serving seven of the world’s ten largest biopharma companies positions hVIVO as a key partner for major pharmaceutical groups and diversifies customer exposure.

Client involvement at the event suggests public endorsement of hVIVO’s commercial proposition and growth trajectory. This external validation addresses investor concerns about client satisfaction, contract renewals, and orderbook sustainability. The announcement notes positive client engagement across hVIVO’s integrated services and multiple opportunities to convert additional revenue through the remainder of 2026, confirming that orderbook growth is driven by genuine demand rather than isolated contract wins.

Expanding Therapeutic Areas Signal Broader Market Opportunities

hVIVO continues to observe strong demand in infectious disease, respiratory, and cardiometabolic programs, along with growing interest in early-phase CRO and laboratory capabilities. This therapeutic diversification indicates that orderbook growth is not reliant on any single disease area or trend, supporting more resilient revenue streams. The increased focus on early-phase CRO services signals hVIVO’s expansion beyond its human challenge trial specialization into the wider contract research organization market.

Infectious disease programs remain a key growth area, reflecting heightened pharmaceutical investment following pandemic preparedness awareness. Respiratory and cardiometabolic markets also offer sustained demand for clinical development services. The growing integration of laboratory and trial services suggests clients are consolidating vendors, enhancing cross-selling opportunities and revenue diversification.

UK and Germany Operations Provide Geographic Diversification and EU Market Access

hVIVO’s wholly owned sites and laboratories in the UK and Germany offer geographic diversification and enable service delivery to European pharmaceutical companies and global subsidiaries. The German operations extend the company’s continental European reach while London headquarters host the world’s largest human challenge trial quarantine facility. This dual-geography platform enhances operational resilience and supports clients navigating regulatory jurisdictions, with shared infrastructure driving cost efficiencies.

Although revenue by geography was not disclosed, the presence in both markets indicates established geographic diversification. For investors concerned about post-Brexit impacts on UK clinical research, the German facilities demonstrate hVIVO’s commitment to maintaining substantial European operations and EU access.

Unified Branding Strategy Boosts Market Presence and Commercial Prospects

Management’s consolidation of consulting, clinical trials, human challenge trials, and laboratory services under the single hVIVO brand marks a strategic advancement. Previously operating under separate brands or units, this unified approach enhances market visibility, simplifies client engagement, and positions hVIVO as an integrated partner rather than fragmented service providers.

The announcement credits the one-brand strategy with driving improved commercial activity and enabling services to be contracted under the hVIVO name rather than distinct units. This integration benefits clients by simplifying vendor management and fostering comprehensive engagement, supporting cross-selling and deeper relationships. The strategy has contributed to a 45% increase in proposal volumes and the more than doubling of the orderbook, indicating positive market reception and sustained momentum into H2 2026.

Board Confidence Supported by Contracted Revenue Visibility and Expanding Growth Pipeline

The board expresses strong confidence in the group’s business model, supported by the significantly expanded orderbook, clear visibility of contracted revenues, and a growing pipeline across all service lines. This reassurance is notable given the H1 profitability decline and provides explicit guidance on business sustainability and growth prospects. The emphasis on contracted revenues offers measurable near-term performance visibility, reducing investor uncertainty.

The expanding pipeline suggests that orderbook growth represents the start of sustained new business conversion, with additional contract opportunities expected through the remainder of 2026. This outlook, combined with diversified services and a robust balance sheet, underpins management’s positive expectations for future performance and strategic positioning.